Synergistic activity of tafasitamab and metronomic chemotherapy on diffuse large B-cell lymphoma through inhibition of the AKT/mTOR signaling pathway

Synergistic activity of tafasitamab and metronomic chemotherapy on diffuse large B-cell lymphoma through inhibition of the AKT/mTOR signaling pathway

Abstract Tafasitamab is a novel humanized anti-CD19 monoclonal antibody, designed for the treatment of B-cell malignancies. Our study aims to enhance the direct, non-immune-mediated, activity of tafasitamab (TAFA) with the combination of metronomic chemotherapy (mCHEMO), including vinorelbine (mVNR)...

Full description

Saved in:
Bibliographic Details
Main Authors: Marta Banchi, Maria Christina Cox, Paola Orlandi, Arianna Bandini, Fabio Stefanelli, Silvio Chericoni, Guido Bocci
Format: Article
Language:English
Published: Nature Portfolio 2025-04-01
Series:Scientific Reports
Subjects:
Diffuse large B-cell lymphoma
Metronomic chemotherapy
Vinorelbine
Etoposide
Tafasitamab
Online Access:https://doi.org/10.1038/s41598-025-95476-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-95476-y

Similar Items